Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Setidegrasib vs Docetaxel in KRAS G12D-mutated Advanced NSCLC
NCT07566052Phase 3Recruiting
- Sponsor
- Astellas Pharma
- Start
- Aug 2026
- Primary completion
- Jun 2030
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 3
01
Overview
A Phase 3 trial of setidegrasib in non-small cell lung cancer (NSCLC), sponsored by Astellas Pharma. Started Aug 2026; status: recruiting.
02
Drugs
setidegrasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07566052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07566052.